There is a need to develop targeted therapies for patients with triple-negative breast cancer (TNBC), as the expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) in TNBC are downregulated. Here, ERBB2 is linked to triple-negative breast carcinoma.